Mazankowski Alberta Heart Institute Starts Study Comparing Ventripoint Heart Analysis
to Contrast Enhanced 2D Echocardiography
Toronto, Ontario, July 17, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to announce that the Mazankowski Alberta Heart Institute in Edmonton, Alberta has begun a study to evaluate the ability of the Ventripoint VMS+ heart analysis system to analyze poor quality images, where contrast enhanced 2D echocardiography would normally be performed to get better images.
“We are very pleased to have such a high profile cardiac institution using our system to improve patient care and outcomes,” commented Desmond Hirson, President of Ventripoint.
In 10-20% of patients the images collected by standard 2D ultrasound are not clear enough to allow for interpretation using conventional methods. Using the artificial intelligence (AI) approach embedded in the VMS+ heart analysis system, the standard images can be analyzed. Normally in these patients, a second exam is immediately performed using the injection of a contrast media, which enhances the ability to see the heart walls and allows for conventional analysis in most cases.
The reduction in the number of contrast-enhanced 2D echo studies would represent a significant savings in time and costs for echocardiology departments. It would also reduce the need to inject the patient with contrast media. The use of contrast-enhanced ultrasound is increasing in the western world with the burgeoning population of heavier people making it more difficult to obtain clear images using ultrasound.
The clinical study is expected to take about three months and include 40-50 patients.
About Mazankowski Alberta Heart Institute
The Mazankowski Alberta Heart Institute in Edmonton is a world leader in complex cardiac care and surgery. With a collaborative approach, its team of highly skilled cardiologists, cardiovascular surgeons, cardiac care professionals, researchers and educators is advancing the prevention, detection, treatment and study of cardiovascular disease.
In other news, on June 22, 2018 the Board of Directors granted a total of 325,000 common share stock options to three officers and 300,000 stock options to four independent directors of the Company. All options are exercisable at $0.31 per share until the fifth anniversary date of the grant.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.